Stock Market & Financial Investment News

News Breaks February 5, 2013 07:28 EDT GILD Gilead price target raised to $49 from $45 at Stifel Nicolaus Stifel Nicolaus increased its price target on Gilead after the company reported that its sofosbuvir drug, a Hepatitis C treatment, met its endpoints in Phase III trials. The firm expects additional data on the drug to move the stock higher next month, and it maintains a Buy rating on the stock. News For GILD From The Last 14 Days Check below for free stories on GILD the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 20, 2013 07:34 EDT GILD UBS to host a conference Subscribe for More Information May 16, 2013 11:50 EDT GILD Celgene, Gilead lower after new data published at ASCO Subscribe for More Information May 15, 2013 18:32 EDT GILD Gilead announces response data from Phase 2 study of Idelalisib Subscribe for More Information May 13, 2013 09:39 EDT GILD Active equity option families trading Active equity option families trading on open according to Track Data: AAPL C TSLA LVS GILD FSLR Sign up for a free trial to see the rest of the stories you've been missing.